Hims, Novo Nordisk

Novo Nordisk Earnings Are Soon. It’s All About Weight-Loss Drug Sales.
When Novo Nordisk reports earnings Wednesday morning, investors will be seeking reassurance that they haven’t overestimated the market for the new GLP-1 weight-loss medicines. When Novo’s competitor Eli Lilly reported its earnings last week,
Hims Reports Strong Earnings, Novo Nordisk Copycat Drug Coming in 2025
Hims & Hers Health reported third-quarter results that topped Street expectations Monday and said it plans to release a generic version of a Novo Nordisk diabetes and weight-loss drug as early as next year.
Hims & Hers to sell generic weight loss drug in 2025
Telehealth platform Hims & Hers will begin offering a generic version of liraglutide, a GLP-1 weight loss drug, to its customers in 2025, Quartz reported Nov. 4.
Hims & Hers Health plans to offer generic version of Novo Nordisk's diabetes drug in 2025
Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025. "We have already confirmed a core supplier for this addition and over the next few months expect to finish completing test and batch validation,
Hims & Hers Stock Jumps. A Generic Version of Novo Nordisk Diabetes Drug Is Close.
Telehealth company Hims & Hers said late Monday in an earnings update that it plans to launch a generic version of Novo Nordisk’s diabetes drug as soon as 2025. It reported strong quarterly earnings.
Weight loss drug industry injects wealth into Novo Nordisk home country
Drugs Ozempic and Wegovy have slimmed down Hollywood stars — and millions of non-celebrities worldwide— while adding great ...
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
Those market dynamics will again be in focus when Novo reports results for its diabetes drug Ozempic and weight-loss ...
Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?
Novo Nordisk is expected to report third-quarter earnings on Wednesday. Stock up 8.55% in a year, 7.45% year-to-date.
Seeking Alpha1h
Novo Nordisk: A GLP-1 Leader Faces Increasing Competition
Novo Nordisk remains a sell due to increased competition and regulatory risks, despite its leadership in the diabetes and ...
CBS News on MSN2d
Novo Nordisk's obesity-fighting drugs are fattening Denmark's economy while shrinking other sectors
Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed ... knew Ozempic and Wegovy's success could impact the ...
Patients Are Suing Over Alleged Side Effects of Weight-Loss Drugs
These drugs are collectively known as GLP-1 agonists because they mimic the body’s natural hormone GLP-1, which regulates ...
Fortune on MSN1d
Danish town where weight-loss wonder drug Ozempic is made suffers from the highest rates of overweight children in Denmark
A more tragic irony in the town is an obesity crisis among residents living in the shadow of the massive Wegovy-making plant.
BMJ8d
Weight loss drugs: Regulator reprimands Novo Nordisk over promotion
The Danish drug company Novo Nordisk has been sanctioned by the UK pharmaceutical industry regulator over the way it has ...
Reuters on MSN1d
Analysis-Americans hungry for weight-loss drugs grapple with supply and insurance hurdles
(Reuters) - Americans are still eagerly seeking prescriptions for Eli Lilly and Novo Nordisk's weight-loss and ...